Loading filters...
Publications per Year (553 total)
1
·
2
·
2
1995
1
·
3
·
4
·
1
·
2
2000
3
·
9
·
8
·
9
·
19
2005
15
·
20
·
13
·
15
·
21
2010
15
·
16
·
21
·
22
·
17
2015
21
·
44
·
31
·
18
·
29
2020
22
·
34
·
38
·
23
·
39
2025
15
·
Loaded
Click to load
50 / 553 papers loaded(scroll for more)
20266 papers
GeneralResectable (I-III)2026
Is pathological complete response a surrogate for overall survival in neoadjuvant clinical trials for gastroesophageal adenocarcinoma?
Leite LF et al. Eur J Cancer. 2026
ImmunotherapyResectable (I-III)2026
Neoadjuvant immunochemoradiotherapy with nivolumab, paclitaxel, and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma.
Huang TC et al. Br J Cancer. 2026
GeneralResectable (I-III)2026
Prognostic Impact of Postoperative Complications After Neoadjuvant Therapy Followed by Esophagectomy for Esophageal Cancer: An Exploratory Analysis of Phase III Trial JCOG1109.
Booka E et al. Ann Surg. 2026
GeneralResectable (I-III)2026
Prognostic factors for paraconduit hernia in adult patients post-esophagectomy for cancer: a systematic review.
Abdel Fattah AR et al. Dis Esophagus. 2026
ImmunotherapyResectable (I-III)2026
PET/CT-Guided Neoadjuvant Tislelizumab Plus Chemotherapy/Chemoradiotherapy for Resectable Esophageal Squamous Cell Carcinoma: RATIONALE-213 Final Analysis.
Yang Y et al. Clin Cancer Res. 2026
GeneralAll Stages2026
ISDE guidelines on the management of cT2N0 esophageal cancer.
Kohn GP et al. Dis Esophagus. 2026
20252 papers
GeneralResectable (I-III)2025
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY et al. N Engl J Med. 2025
GeneralAll Stages2025
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.
Shitara K et al. J Clin Oncol. 2025
20241 papers
GeneralAdvanced/Metastatic (IV)2024
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
Randon G et al. Lancet Oncol. 2024
202320 papers
GeneralAll Stages2023
Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study.
Elliott JA et al. Ann Surg. 2023
ImmunotherapyAdvanced/Metastatic (IV)2023
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial.
Zhu Y et al. Lancet Oncol. 2023
HER2-positiveAdvanced/Metastatic (IV)2023
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study.
Van Cutsem E et al. Lancet Oncol. 2023
GeneralAll Stages2023
Survival and perioperative outcomes of octo- and nonagenarians with resectable esophageal carcinoma.
Ahmed N et al. Dis Esophagus. 2023
GeneralResectable (I-III)2023
Treatment burden and cost-effectiveness analysis of the neoadjuvant CROSS regimen in esophageal squamous cell carcinoma: a multicenter retrospective study.
Gao X et al. Dis Esophagus. 2023
GeneralResectable (I-III)2023
Pathological complete response in multimodal treatment of esophageal cancer: a retrospective cohort study.
Hipp J et al. Dis Esophagus. 2023
GeneralAll Stages2023
Impact of Lymph Node Dissection on Survival After Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Guo X et al. Ann Surg. 2023
GeneralAll Stages2023
Durvalumab and PET-Directed Chemoradiation in Locally Advanced Esophageal Adenocarcinoma: A Phase Ib/II Study.
Cowzer D et al. Ann Surg. 2023
GeneralAll Stages2023
Oncological outcomes of standard versus prolonged time to surgery after neoadjuvant chemoradiotherapy for oesophageal cancer in the multicentre, randomised, controlled NeoRes II trial.
Nilsson K et al. Ann Oncol. 2023
GeneralAdvanced/Metastatic (IV)2023
S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma-final results of the randomized AIO MATEO phase II trial.
Stocker G et al. ESMO Open. 2023
GeneralResectable (I-III)2023
Risk Factors for Tumor Positive Resection Margins After Neoadjuvant Chemoradiotherapy for Esophageal Cancer: Results From the Dutch Upper GI Cancer Audit: A Nationwide Population-Based Study.
Defize IL et al. Ann Surg. 2023
ImmunotherapyAdvanced/Metastatic (IV)2023
Health-Related Quality of Life With Nivolumab Plus Chemotherapy Versus Chemotherapy in Patients With Advanced Gastric/Gastroesophageal Junction Cancer or Esophageal Adenocarcinoma From CheckMate 649.
Moehler M et al. J Clin Oncol. 2023
GeneralAll Stages2023
Postoperative and Pathological Outcomes of CROSS and FLOT as Neoadjuvant Therapy for Esophageal and Junctional Adenocarcinoma: An International Cohort Study From the Oesophagogastric Anastomosis Audit (OGAA).
Ann Surg. 2023
HER2-positiveAdvanced/Metastatic (IV)2023
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Advanced Gastric or Gastroesophageal Junction Cancer.
Kim CG et al. J Clin Oncol. 2023
GeneralAll Stages2023
Neoadjuvant versus definitive chemoradiation in locally advanced esophageal cancer for patients of advanced age or significant comorbidities.
Jensen GL et al. Dis Esophagus. 2023
ImmunotherapyAdvanced/Metastatic (IV)2023
Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer.
Maron SB et al. Clin Cancer Res. 2023
ImmunotherapyAll Stages2023
Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
Wang H et al. Eur J Cancer. 2023
HER2-positiveAdvanced/Metastatic (IV)2023
Comprehensive biomarker analysis of long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma.
Porth I et al. Eur J Cancer. 2023
GeneralAll Stages2023
Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer.
Matsuda S et al. Dis Esophagus. 2023
GeneralAll Stages2023
Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study.
Schuring N et al. Dis Esophagus. 2023
20222 papers
GeneralAdvanced/Metastatic (IV)2022
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study.
Shen L et al. J Clin Oncol. 2022
ImmunotherapyAll Stages2022
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Kang YK et al. Lancet Oncol. 2022
202019 papers
GeneralAll Stages2020
Total Lesion Glycolysis Assessment Identifies a Patient Fraction With a High Cure Rate Among Esophageal Adenocarcinoma Patients Treated With Definitive Chemoradiation.
Harada K et al. Ann Surg. 2020
HER2-positiveAdvanced/Metastatic (IV)2020
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY et al. Lancet Oncol. 2020
GeneralAll Stages2020
Quantitative Assessment of Blood Flow in the Gastric Conduit With Thermal Imaging for Esophageal Reconstruction.
Nishikawa K et al. Ann Surg. 2020
GeneralAdvanced/Metastatic (IV)2020
Hospital volume and beyond first-line palliative systemic treatment in metastatic oesophagogastric adenocarcinoma: A population-based study.
Dijksterhuis WPM et al. Eur J Cancer. 2020
GeneralAdvanced/Metastatic (IV)2020
Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J et al. Clin Cancer Res. 2020
HER2-positiveAdvanced/Metastatic (IV)2020
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Shitara K et al. N Engl J Med. 2020
HER2-positiveAdvanced/Metastatic (IV)2020
Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Makiyama A et al. J Clin Oncol. 2020
GeneralAll Stages2020
Tracheal resection and anterior mediastinal tracheostomy in the multidisciplinary treatment of esophageal cancer with tracheal invasion.
Yamasaki M et al. Dis Esophagus. 2020
ImmunotherapyAdvanced/Metastatic (IV)2020
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Catenacci DVT et al. Lancet Oncol. 2020
GeneralAll Stages2020
Treatment protocol for secondary esophageal reconstruction using 'supercharged' colon interposition flaps.
Esmonde N et al. Dis Esophagus. 2020
GeneralResectable (I-III)2020
Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study.
Klevebro F et al. Dis Esophagus. 2020
ImmunotherapyAdvanced/Metastatic (IV)2020
Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A et al. Eur J Cancer. 2020
GeneralAll Stages2020
Resection of the irradiated esophagus: the impact of lymph node yield on survival.
Esposito VR et al. Dis Esophagus. 2020
GeneralResectable (I-III)2020
Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study.
Wong IYH et al. Ann Surg. 2020
GeneralResectable (I-III)2020
Adverse Biology in Adenocarcinoma of the Esophagus and Esophagogastric Junction Impacts Survival and Response to Neoadjuvant Therapy Independent of Anatomic Subtype.
Donlon NE et al. Ann Surg. 2020
GeneralResectable (I-III)2020
Surgical Morbidity and Mortality From the Multicenter Randomized Controlled NeoRes II Trial: Standard Versus Prolonged Time to Surgery After Neoadjuvant Chemoradiotherapy for Esophageal Cancer.
Nilsson K et al. Ann Surg. 2020
HER2-positiveAdvanced/Metastatic (IV)2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Park H et al. JAMA Oncol. 2020
GeneralAll Stages2020
Transdiaphragmatic herniation after transthoracic esophagectomy: an underestimated problem.
Fuchs HF et al. Dis Esophagus. 2020
GeneralResectable (I-III)2020
Failure to Cure in Patients Undergoing Surgery for Esophageal Carcinoma: Hospital of Surgery Influences Prospects for Cure: A Nation-wide Cohort Study.
Voeten DM et al. Ann Surg. 2020